Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
<h4>Objectives</h4> <p>To evaluate the benefits and harms of oral centrally acting antiobesity medicinal products in pivotal trials.</p> <h4>Methods</h4> <p>The European Medicines Agency and Federal Drug Administration websites, PubMed, and ClinicalTrials....
Autori principali: | Onakpoya, I, Collins, D, Bobrovitz, N, Aronson, J, Heneghan, C |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
Wiley
2018
|
Soggetti: |
Documenti analoghi
Documenti analoghi
-
Lorcaserin in obesity: minimal benefits and ill-defined harms
di: Onakpoya, I, et al.
Pubblicazione: (2019) -
Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials
di: Onakpoya, I, et al.
Pubblicazione: (2019) -
Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials
di: Igho J Onakpoya, et al.
Pubblicazione: (2019-01-01) -
Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
di: Onakpoya, I, et al.
Pubblicazione: (2016) -
Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
di: Onakpoya, I, et al.
Pubblicazione: (2017)